-
January 04, 2023Elpiscience to Present Its Novel Immunotherapies at Biotech Showcase™ during J.P. Morgan Week 2023
Elpiscience today announced that it will present the latest progress of its innovative molecules and powerful antibody generation platforms at the Biotech Showcase™ conference during J.P.Morgan
-
December 23, 2022Elpiscience Announces China CDE IND Clearance of ES014, a First in Class Anti-CD39xTGF-β Bispecific Antibody for Patients with Advanced Solid Tumors
Elpiscience today announced that the China Center of Drug Evaluation (CDE) has cleared Elpiscience’s Investigational New Drug Application (IND) for ES014 to initiate a Phase 1 clinical study for
-
November 18, 2022Elpiscience Announces Studies Presented at SITC 2022 Annual Meeting
Elpiscience presented positive studies for its innovative immunotherapeutic molecules at the SITC 2022 Annual Meeting
-
October 26, 2022Elpiscience Announces Five Poster Presentations at Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting
Elpiscience announced it will have five poster presentations at the SITC 2022 Annual Meeting.
-
May 09, 2022Elpiscience Announces FDA IND Clearance of ES014, a First in Class Anti-CD39xTGF-β Bispecific Antibody for Patients with Advanced Solid Tumors
ES014 is a first in class anti-CD39xTGF-β bispecific antibody (bsAb) that simultaneously targets the CD39-adenosine and TGF-β pathways.
-
May 06, 2022Positive Interim ES104 Phase 2 Data Reported in Combination with Paclitaxel in Biliary Tract Cancers
ES104 in combination with paclitaxel showed a high ORR including responses in all four BTC subtypes and good overall tolerability consistent with prior studies.
